I thought this was actually already the case with clinicaltrials.gov and it is apparently having a profound effect: http://www.nature.com/news/registered-clinical-trials-make-p...
However, a recent review in NEJM explained how it is time consuming and expensive to apply for expanded-access and often the pharmaceutical companies refuse to distribute the drugs even after the FDA grants expanded-access.
http://www.nejm.org/doi/full/10.1056/NEJMhle1409465
"Compassionate use" is a separate, but related concept with different rules than "expanded access". And in the EU expanded access is often called "named-patient".
Why is there dependence on drug companies ? distributing drugs bought in Europe or elsewhere is pretty easy.And as for drug companies being protected from american litigation - if they don't sell it on u.s. soil, they are not responsible in u.s. courts, right?
As for the process being complex and expensive, is there work being done to solving this, with regards to EMA approved drugs ?
And no, her doctor isn't some quack who regularly prescribes unapproved medicine. Apparently this particular drug is approved in Canada and Europe, but the company that makes it is small enough that they haven't yet decided to apply for FDA approval because of the cost. (Or at least, that's what I've been told.)
The FDA is too conservative with many metrics, and too aggressive with others. The clinical trial pipeline is tortuously slow for everyone involved-- the EU equivalent agency has done a lot to accelerate the process fruitfully. Eclipsing these FDA malregulations is the problem of transparency; if the FDA forced clinical trials to publish 100% of their data rather than only the positive results, we'd have a better medicine producing industry.